Items
0
Delivery to
Bangladesh
All
Hello, User
Account & Orders
0
Shop By Category
Call for Order
Shop By Category
Loading...
ফার্মেসীর জন্য পাইকারি দামে ঔষধ কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this

Out of Stock
Currently unavailable, please request or choose another variant.
0.00
Notify
Select Quantity
0
Sefety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Enliven. Please consult your doctor.
CONSULT YOUR DOCTOR
Enliven is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Enliven is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. Lactating women should not breastfeed while using this drug and one month after stopping it.
UNSAFE
Enliven may cause side effects which could affect your ability to drive.
CAUTION
Enliven should be used with caution in patients with kidney disease. Dose adjustment of Enliven may be needed. Please consult your doctor.
CAUTION
Enliven should be used with caution in patients with severe liver disease. Dose adjustment of Enliven may be needed. Please consult your doctor.
Medical Overview
Introduction
Enliven belongs to the class of medicines known as tyrosine kinase inhibitors. It is used in the treatment of blood cancer (chronic myeloid leukaemia and Acute lymphocytic leukemia) and gastrointestinal stromal tumor. Enliven should be taken with food, but better to have it same time every day to get the most benefit. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. The most common side effects of this medicine include rash, vomiting, abdominal pain and diarrhea. Other than this, water retention and swelling are commonly observed side effects. Let your doctor know if you experience unexpected rapid weight gain. Your doctor may advice for regular monitoring of blood cells and liver function while you are taking this medicine. Do not drive or do anything requiring mental focus if you experience dizziness and blurry vision. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
Uses of Enliven
  • Blood cancer (Chronic myeloid leukaemia)
  • Blood cancer (Acute lymphocytic leukemia)
  • Gastrointestinal stromal tumour
Side effects of Enliven
Common
  • Abdominal pain
  • Diarrhea
  • Fatigue
  • Muscle cramp
  • Musculoskeletal (bone, muscle or joint) pain
  • Nausea
  • Rash
  • Vomiting
How to use Enliven
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Enliven is to be taken with food.
How Enliven works
Enliven is an anti-cancer medication. A protein enzyme, bcr-abl tyrosine kinase, responsible for the growth of abnormal proliferation of cancer cells. This medicine inhibits the proliferation and induces apoptosis (planned cell death) in bcr-abl positive cells (cancer cells). This is how it works to stop or slow the spread of cancer.
What if you forget to take Enliven?
If you miss a dose of Enliven, skip it and continue with your normal schedule. Do not double the dose.
Quick Tips
  • Always take it with food and a full glass of water to prevent nausea.
  • It may cause dizziness or blurred vision. Do not drive or do anything requiring concentration until you know how it affects you.
  • Water retention and swelling are very common side effects of Enliven. Notify your doctor if you have unexpected rapid weight gain.
  • Do not change the dose or discontinue use without consulting your doctor.
  • Notify your doctor about all the medications you are taking, including over the counter medicines and dietary supplements.
  • Your doctor may get regular blood tests done to monitor your liver function and the number of blood cells in your blood.
Brief Description
Indication
Chronic myeloid leukaemia, Acute lymphoblastic leukaemia, Myelodysplastic disease, Hypereosinophilic syndrome, Mastocytosis, Dermatofibrosarcoma protuberans, Malignant gastrointestinal stromal tumours
Administration
Should be taken with food and large glass of water.
Adult Dose
Acute Lymphoblastic Leukemia Indicated for adults with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) 600 mg PO qDay Myelodysplastic/Myeloproliferative Diseases Indicated in adults with myelodysplastic/ myeloproliferative diseases associated with platelet-derived growth factor receptor gene re-arrangements as determined with an FDA-approved test 400 mg PO qDay Hypereosinophilic Syndrome/Eosinophilic Leukemia Indicated for adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR-alpha fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR-alpha fusion kinase negative or unknown 400 mg PO qDay In patients with demonstrated F1P1L1-PDGFR-alpha fusion kinase: 100 mg PO qDay; may increase to 400 mg qDay in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy Chronic Myeloid Leukemia Chronic phase Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase 400 mg PO qDay Chronic phase after failure of interferon-alpha therapy: May increase to 600 mg/day in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6-12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response Accelerated phase or blast crisis 600 mg PO qDay May increase to 400 mg PO q12hr in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6-12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response Dermatofibrosarcoma Protuberans Indicated for adults with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans 400 mg PO q12hr Mastocytosis Indicated for adults with aggressive systemic mastocytosis without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown Without D816V c-Kit mutation: 100 mg PO qDay c-Kit mutational status unknown: 400 mg PO qDay if not responding to other therapies ASM associated with eosinophilia (a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR-alpha): 100 mg PO qDay initially, may increase to 400 mg/day in absence of adverse effects if response to therapy is insufficient Gastrointestinal Stromal Tumors Unresectable and/or metastatic malignant GIST 400 mg PO qDay; may increase to 400 mg BID in patients showing clear signs or symptoms of disease progression at a lower dose and in the absence of severe adverse drug reactions Adjuvant treatment following complete gross resection of GIST 400 mg PO qDay x3 years Hepatic impairment: Severe: Reduce dose by 25%.
Child Dose
Chronic Myeloid Leukemia Indicated for newly diagnosed adult and pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase <1 year: Safety and efficacy not established >1 year: 340 mg/m²/day PO; not to exceed 600 mg/day Acute Lymphoblastic Leukemia Indicated for treatment of newly diagnosed children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) <1 year: Safety and efficacy not established >1 year: 340 mg/m²/day PO; not to exceed 600 mg/day
Contraindication
Hypersensitivity. Lactation.
Mode of Action
Imatinib, is a tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It blocks proliferation and induces apoptosis in BCR-ABL positive cell lines, as well as fresh leukaemic cells from Philadelphia chromosome positive CML. Imatinib also inhibits receptor kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, PDGF- and SCF-mediated cellular events.
Precaution
Cardiac disease or increased risk for CHF. Monitor for signs of severe fluid retention. Monitor CBC regularly. Renal and hepatic impairment. Monitor LFTs. Pregnancy. Lactation: Imatinib and its active metabolite are excreted into human milk; advise a lactating woman not to breastfeed during treatment and for 1 month after last dose
Side Effect
>10% Edema (53%),Neutropenia (Grade 3: 7-27%; Grade 4: 3-48%),Nausea (43%),Muscle cramps (35%),Musculoskeletal pain (34%),Thrombocytopenia (Grade 3: 1-31%; Grade 4: 1-34%),Rash (32%),Fatigue (31%),Diarrhea (30%),Headache (29%),Arthralgia (27%),Abd pain (23%),Myalgia (21%),Nasopharyngitis (19%),Hemorrhage (19%),Vomiting (15%),Dyspepsia (15%),Cough (13%),Dizziness (13%),URT infection (13%),Fever (12%),Weight gain (12%),Hepatotoxicity (6-12%),Insomnia (11%) 1-10% Flushing,Palpitation,Dry skin,Erythema,Metabolic hyperglycemia,Stomatitis/mucositis,Lymphopenia <1% Aplastic anemia,Atrial fibrillation,Avascular necrosis,Cardiac failure,Cardiogenic shock,Embolism,Eosinophilia Potentially Fatal: Hepatotoxicity, cerebral oedema, increased intracranial pressure, papilloedema. Severe fluid retention resulting in pleural and pericardial effusion, pulmonary oedema and ascites. Rarely, GI perforation.
Interaction
Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.
ফার্মেসীর জন্য পাইকারি দামে ঔষধ কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this

Out of Stock
Currently unavailable, please request or choose another variant.
0.00
Notify
Select Quantity
0
Additional Offers
Cashback
৳100
For purchasing above ৳5000+
Cashback
৳80
For purchasing above ৳4000+
Cashback
৳60
For purchasing above ৳3000+
Cashback
৳40
For purchasing above ৳2000+
Cashback
৳20
For purchasing above ৳1000+
Similar Products
see all
LoadingLoadingLoadingLoadingLoadingLoading
More from Orion Pharma Ltd.
see all
LoadingLoadingLoadingLoadingLoadingLoading
Disclaimer
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.